• There are no suggestions because the search field is empty.

End of year message from Jukka Tapaninen, CEO at Aiforia Technologies

End of year message from Jukka Tapaninen, CEO at Aiforia, on key highlights, partnerships, and projects from our pharmaceutical and clinical projects.
Written by Aiforia

2020 was an exceptional and challenging year. Like many others we at Aiforia had to adapt to the new circumstances posed by the ongoing COVID-19 pandemic. Despite the global turbulence we continue to serve scientists and medical professionals across preclinical, academic, and clinical labs around the globe. 

The novel coronavirus pandemic forced much of the world’s population to work remotely and adjust their routines. The need for cloud-based solutions has therefore never been higher. This changing landscape and demand is certainly reflected in our growth. In 2020 the number of Aiforia users increased by a record setting 87% to a total of over 3,000 users in over 50 countries.

I would like to thank our customers, partners and of course the team at Aiforia for their diligence and resilience during these difficult times. Our team of scientists, software developers, and business professionals are key in driving our accomplishments from the past year; to name a few:

2020 highlights

  • Secured a U.S. patent for high-speed AI training tool in pathology related image analysis
  • Formed Aiforia’s Scientific Advisory Board representing world-class expertise in clinical diagnostics, personalized medicine, digital and computational pathology 
  • Won our biggest deal to date with one of the top 20 largest pharmaceutical companies in the world: a US-based organization looking to accelerate their preclinical workflows with AI 
  • Partnered with NeuroScience Associates to build the world’s first full brain reference map of the neurodegenerative disease ALS
  • Acquired our first Japanese customer: one of the largest medical devices companies in the country 
  • Released many highly-sought after tools for enhanced AI-enabled image analysis: Instance Segmentation, Transfer Learning, External Validation tools and others 
  • The multitude of exciting projects and partnerships with our customers from Charles River Laboratories, the Mayo Clinic, the University of Oxford, and many more
Aiforia Users around the world


During the year we also made huge strides in developing our clinical offering. Aiforia presented a preview of its clinical solutions for AI-assisted diagnostics of prostate cancer and in 2021 we will unveil our platform combining powerful AI-based image analytics and integrated image viewers with reporting tools to support pathologists' decision making in the clinical workflow. Our science team is also developing a suite of core AI models for the diagnosis of some of the world’s most common cancers such as prostate and breast, as well as for other major diseases: malaria, fatty liver diseases, and more. 

Looking ahead I am excited for Aiforia, our partners and our customers to keep building on these successes. Our mission is to outfit healthcare professionals with the digital solutions they need for the shifting landscape of medicine. This rings particularly true as we turn the corner on a new year, a new normal, and a continued need to adapt our way of working. 

I would like to wish you all a happy and healthy holiday period! 

Yours sincerely,

Jukka Tapaninen 


Aiforia Technologies